C Diff Drug Development

A novel oral microbial therapy under development by Vedanta Biosciences reduced the risk of recurrence of Clostridioides difficile infection in a phase 2 clinical trial.

The increased research and development activities for developing and launching new drugs are expected to fuel growth in the Clostridium difficile infection...

J.P. Morgan has initiated Seres Therapeutics (MCRB) with a neutral rating saying that it will take time for SER-109 to have its reimbursement take place.

Small-molecule inhibitors offer many advantages for manipulating the gut microbiome, both as tool compounds and as potential therapeutics. This Review highlights recent examples of inhibitors that target gut bacterial enzymatic activity as well as the challenges and opportunities associated with their design and development.

RBX2660 and Vowst are now both approved for the prevention of recurrent C. difficile infections.

This clinical trial compares the efficacy of 2 different doses of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, and placebo in preventing recurrence of Clostridioides difficile infection among adults at high risk.

A novel oral microbiome-directed therapy called VE303 successfully prevented recurrent Clostridioides difficile infection in adults at high risk for recurrence, researchers found.

Seres Therapeutics took 12 years to develop one of the first microbiome drugs in the U.S. Here's a timeline of major milestones and setbacks along the way.

Seres Therapeutics (MCRB) shares surged to reach a four month high on Monday as the company awaits the FDA decision on its lead candidate SER-109. Read more here.

This clinical trial compares the efficacy of 2 different doses of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, and placebo in preventing recurrence of Clostridioides difficile infection among adults at high risk.

J.P. Morgan has initiated Seres Therapeutics (MCRB) with a neutral rating saying that it will take time for SER-109 to have its reimbursement take place.

This clinical trial compares the efficacy of 2 different doses of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, and placebo in preventing recurrence of Clostridioides difficile infection among adults at high risk.

A scientific poster highlighting a novel pharmacologic property of oral ibezapolstat for C. difficile Infection likely related to its unique mechanism of action was presented at ECCMID 2023An update... | April 19, 2023

SOMERVILLE, Mass., April 18, 2023 -- Finch Therapeutics Group, Inc. , a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has... | April 18, 2023

JAMA publication includes in-depth safety and efficacy results from Vedanta’s successful Phase 2 study of VE303 ... | April 17, 2023

[This corrects the article DOI: 10.3389/fmicb.2023.1110541.].

About The Study: Among adults with laboratory-confirmed Clostridioides difficile infection (CDI) with one or more prior CDI episodes in the last six months and those with primary CDI at high risk for recurrence, high-dose VE303 (a novel oral microbiome-directed therapy composed of nonpathogenic, nontoxigenic, commensal strains of Clostridia) prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings.

ClinicalTrials.gov Identifier: NCT03788434.

Clostridioides difficile infection (CDI) causes severe diarrhea and colitis, leading to significant morbidity, mortality, and high medical costs worldwide. Oral vancomycin, a first-line treatment for CDI, is associated with a high risk of recurrence, necessitating novel therapies for primary and rec …

FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference - read this article along with other careers information, tips and advice on BioSpace

Market Tree Research has added a new key research reports covering C DIFFICILE INFECTION DRUG market The study aims to provide global investors with a game changing decision making tool covering key fundamentals of the C DIFFICILE INFECTION DRUG market ...

London, UK | April 06, 2023 09:53 AM Eastern Daylight Time --p /Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) ch

A team of researchers from Harvard University has developed a suite of Escherichia coli Nissle 1917 (EcN), named PRObiotic type 3 secretion E. coli therapeutic (PROT3ECT), engineered to secrete a TNF-α nanobody directly into the gut to reduce inflammation in a chemically induced inflammatory bowel disease (IBD) mouse model.

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) said data from a study on one of its lead assets has been peer-reviewed and published in Microbiology Spectrum. A...

Researchers have succeeded in developing an E. coli-based 'smart microbe' that secretes therapeutic payloads, including antibodies, into the gut. The genetically modified beneficial strain of bacteria blocks intestinal inflammation in a preclinical model of inflammatory bowel disease and has the potential to treat intestinal-based diseases.

A new study by researchers at Intermountain Health and Stanford University found that overprescribing and inappropriate prescribing of antibiotics is not only leading to antibiotic resistance, but also causing significant patient harm. Dr. Harris Carmichael, lead investigator of the study and a hospitalist at Intermountain Health, said the study, published in the Journal of Internal […]